Characteristic | Haloperidol | Risperidone | Olanzapine | Quetiapine | Total | Sig. | |
---|---|---|---|---|---|---|---|
 |  | N = 23 | N = 21 | N = 18 | N = 18 | N = 80 |  |
Age, year | 74.0 ± 9.9 | 70.1 ± 9.5 | 69.5 ± 15.9 | 73.3 ± 10.7 | 71.8 ± 11.5 | 0.522 | |
Education, year | 5.8 ± 4.5 | 8.7 ± 6.9 | 8.5 ± 6.4 | 7.3 ± 3.9 | 7.5 ± 5.6 | 0.327 | |
Gender, male | 12(52.2) | 8(38.1) | 8(44.4) | 8(44.4) | 36(45) | 0.828 | |
Number of contributing causes of delirium | 1.8 ± 0.5 | 1.9 ± 0.7 | 1.9 ± 0.4 | 2.0 ± 0.8 | 1.9 ± 0.6 | 0.783 | |
Definite cause of delirium | Â | Â | Â | Â | Â | Â | |
Metabolic/endocrine | 6(26.0) | 8(38.0) | 4(22.2) | 5(27.7) | 23(28.7) | 0.759 | |
Systemic infection | 4(17.3) | 3(14.2) | 3(16.6) | 4(22.2) | 14(17.5) | 0.957 | |
Systemic neoplasm | 6(26.0) | 1(4.7) | 3(16.6) | 2(11.1) | 12(15.0) | 0.260 | |
Cerebrovascular | 3(13.0) | 3(14.2) | 0(0.0) | 3(16.6) | 9(11.2) | 0.328 | |
Organ insufficiency | 3(13.0) | 3(14.2) | 8(44.4) | 2(11.1) | 16(20.0) | 0.059 | |
Others | 1(4.3) | 3(14.2) | 0(0.0) | 2(11.1) | 6(7.5) | 0.354 | |
Dose, mg/day | 1.2 ± 0.4 | 1.1 ± 0.3 | 2.9 ± 1.0 | 47.9 ± 17.1 |  |  | |
Chlorpromazine equivalent dose, mg/day | 60.0 ± 21.4 | 56.3 ± 16.8 | 59.8 ± 20.5 | 63.9 ± 22.8 | 59.8 ± 20.4 | 0.192 | |
Duration of medication, day | 4.7 ± 1.6 | 5.1 ± 1.3 | 5.3 ± 1.1 | 4.8 ± 1.7 | 4.9 ± 1.5 | 0.655 | |
Number of subjects assessed, | Baseline | 23(100.0) | 21(100.0) | 18(100.0) | 18(100.0) | 80(100.0) | Â |
 | Day 2 | 18(78.2) | 21(100.0) | 18(100.0) | 15(83.3) | 72(90.0) |  |
Day 4 | 16(69.5) | 18(85.7) | 15(83.3) | 12(66.6) | 61(76.2) | Â | |
 | Day 6 | 14(60.8) | 14(66.6) | 13(72.2) | 12(66.6) | 53(66.2) |  |